- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about Phase 3 Trial
Recent news which mentions Phase 3 Trial
Regeneron-Roche Post Encouraging New Data For COVID-19 Antibody Cocktail
September 30, 2021
From Benzinga
Adagio's COVID-19 Candidate Shows Prolonged Half-Life, Neutralization At Six Months
September 29, 2021
From Benzinga
Novartis Posts New Data Reinforcing Efficacy, Convenience Of Cosentyx Autoinjector In Psoriasis
September 29, 2021
Tickers
NVS
From Benzinga
ViiV Healthcare's Dovato Combo Regime Shows Encouraging Long Term Data In HIV Patients
September 29, 2021
From Benzinga
J&J's Xarelto Tops Aspirin With Fewer Blood Clots In Pediatric Patients
September 27, 2021
Tickers
JNJ
From Benzinga
Pfizer Kick Starts Late-Stage Study For COVID-19 Oral Antiviral For Post-Exposure Prophylaxis
September 27, 2021
Tickers
PFE
From Benzinga
Merck's Keytruda Tops Placebo On Overall Survival Endpoint In Liver Cancer Patients
September 27, 2021
Tickers
MRK
From Benzinga
AstraZeneca - Merck's Lynparza Delays Disease Progression In Prostate Cancer Patients
September 24, 2021
From Benzinga
Valneva Continues To Expand COVID-19 Vaccine Candidate Trials
September 23, 2021
Tickers
VALN
From Benzinga
Vietnam's Health Ministry Approves Phase 2, Phase 3 Cohorts Of Arcturus' COVID-19 Vaccine Trial
September 22, 2021
Tickers
ARCT
From Benzinga
Why Are Dynavax Technologies Shares Skyrocketing Today?
September 22, 2021
Tickers
DVAX
From Benzinga
Corvus Posts Data From Discontinued Mupadolimab COVID-19 Program
September 22, 2021
Tickers
CRVS
From Benzinga
Fast Track Status Expanded For Inventiva's NASH Treatment
September 22, 2021
Tickers
IVA
From Benzinga
FDA Not In Favor Of Summit Therapeutics' Endpoint Change To Pivotal Infection Trials
September 22, 2021
Tickers
SMMT
From Benzinga
Seelos Therapeutics Shares Gain On FDA Approval To Add SLS-005 Regimen In HEALEY ALS Trial
September 21, 2021
Tickers
SEEL
From Benzinga
Ocugen's India-Based Partner Concludes COVID-19 Vaccine Trials In Children: Report
September 21, 2021
Tickers
OCGN
From Benzinga
AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials
September 20, 2021
From Benzinga
Exelixis's Cabometyx Scores FDA Nod In Differentiated Thyroid Cancer; ESMO Presentation
September 20, 2021
Tickers
EXEL
From Benzinga
Novartis' Kisqali Combo Therapy Extends Survival By One Year In Breast Cancer Patients
September 20, 2021
Tickers
NVS
From Benzinga
AstraZeneca Touts Longest Survival Update In Lung Cancer Setting With Imfinzi/Chemo Data
September 20, 2021
From Benzinga
From Benzinga
Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC
September 20, 2021
From Benzinga
Deciphera Presents New Data Across Pipeline At ESMO Congress
September 17, 2021
Tickers
DCPH
From Benzinga
Novartis' Prostate Cancer Therapy Linked To Improved Quality Of Life
September 17, 2021
Tickers
NVS
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.